Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
TAK-243 by Millennium Pharmaceuticals for Lymphoma: Likelihood of Approval
TAK-243 is under clinical development by Millennium Pharmaceuticals and currently in Phase I for Lymphoma. According to GlobalData, Phase I...
Ixazomib citrate by Millennium Pharmaceuticals for Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease): Likelihood of Approval
Ixazomib citrate is under clinical development by Millennium Pharmaceuticals and currently in Phase II for Interstitial Lung Diseases (Diffuse Parenchymal...
Ixazomib citrate by Millennium Pharmaceuticals for Primary Progressive Multiple Sclerosis (PPMS): Likelihood of Approval
Ixazomib citrate is under clinical development by Millennium Pharmaceuticals and currently in Phase II for Primary Progressive Multiple Sclerosis (PPMS)....
Ixazomib citrate by Millennium Pharmaceuticals for Relapsing Remitting Multiple Sclerosis (RRMS): Likelihood of Approval
Ixazomib citrate is under clinical development by Millennium Pharmaceuticals and currently in Phase II for Relapsing Remitting Multiple Sclerosis (RRMS)....
Ixazomib citrate by Millennium Pharmaceuticals for Secondary Progressive Multiple Sclerosis (SPMS): Likelihood of Approval
Ixazomib citrate is under clinical development by Millennium Pharmaceuticals and currently in Phase II for Secondary Progressive Multiple Sclerosis (SPMS)....